股价表现 - DexCom (DXCM) 最近的股价为 $133.04，较前一交易日收盘价下跌了 -1.63% [1] - DexCom 过去一个月的股价上涨了 12.27%，超过了医疗行业的涨幅 3.03% 和标普500指数的涨幅 2.7% [2] 财务预期 - DexCom 预计将发布每股收益为 $0.27，同比增长 58.82%，预计营收为 $909.9 亿美元，同比增长 22.71% [3] - DXCM 全年的 Zacks 一致预期为每股收益 $1.74 和营收 $43.1 亿美元，同比增长分别为 +14.47% 和 +18.98% [4] 分析评级 - DexCom 目前的 Zacks Rank 为 3 (Hold)，过去30天内，一致预期的每股收益增长了 1.8% [7] 行业比较 - DexCom 目前的前瞻市盈率为 77.62，高于行业平均值 28.35 [8] - DXCM 的 PEG 比率为 2.35，医疗仪器行业的平均 PEG 比率为 2.35 [9] - 医疗仪器行业在医疗领域中排名第70，位于所有250多个行业的前28% [10] - Zacks Industry Rank 表明，评级较高的行业胜过评级较低的行业，前50%的行业胜过后50%的行业2比1 [11] 建议 - 使用 Zacks.com 可以追踪所有这些影响股价的指标，在未来的交易中保持关注 [12]

A good way to invest in the healthcare industry's continued growth is by targeting businesses that make medical devices. Such equipment aids physicians in surgery, helps patients recover, and can assist people in staying on top of chronic conditions, including hypertension and diabetes.This hasn't exactly been a hot place to invest in, however. Since 2021, the iShares US Medical Devices ETF has risen by just 6%, while the S&P 500 has achieved gains in excess of 36%. But as many investors have been overlooki ...

DexCom公司新产品Stelo获得FDA批准 - DexCom公司股价本周上涨近10%[1] - Stelo是一款小型可穿戴传感器，适用于成年糖尿病患者[3] - FDA已批准Stelo供非糖尿病患者使用，扩大了目标患者群[3] Stelo无需处方即可购买 - 预计将增加产品的需求，扩大潜在市场[4] DexCom的OTC传感器Stelo在减肥治疗期间有应用 - 可帮助患者跟踪健康状况，即使没有保险覆盖[6] Stelo有望成为DexCom未来组合中的关键产品 - 得到强大的基本面支持[8]

DexCom公司 - DexCom (DXCM)是医疗股中表现出色的公司[1] - DexCom目前在Zacks Sector Rank中排名第4[2] - DexCom目前的Zacks Rank为2（买入）[3] - 过去三个月，DXCM全年盈利的Zacks Consensus Estimate上调了2.6%[4] - DXCM今年迄今涨幅约为7.8%，高于医疗股平均涨幅7.2%[5] - DexCom属于医疗-仪器行业，今年迄今涨幅略低于行业平均值8.4%[8] Ambrx Biopharma Inc. - Ambrx Biopharma Inc.（AMAM）今年迄今涨幅为96.6%，表现优异[6] - Ambrx Biopharma Inc.的当前年度一致EPS预估增加了1%[7] - Ambrx Biopharma Inc.属于医疗-生物医学和遗传学行业，行业今年迄今上涨了2.4%[9] - DexCom和Ambrx Biopharma Inc.可能会继续表现强劲，值得关注[10]

DexCom (DXCM) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this medical device company have returned +5.6% over the past month versus the Zacks S&P 500 composite's +3.2% change. The Zacks Medical - Instruments industry, to which DexCom belongs, has gained 3.2% over this period. Now the key question is: Where could the stock be headed in the near term?While media rel ...

DexCom (DXCM) shares ended the last trading session 9.8% higher at $133.72. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.5% loss over the past four weeks.The surge in stock price was likely driven by FDA clearance for Stelo glucose biosensor, available over-the-counter to consumers without a prescription. As an alternative for people without insurance coverage for continuous glucose monitoring sensors like G7, ...

文章核心观点 - 美联储主席鲍威尔表示,美联储今年仍有可能降息 [1][4] - Dexcom获得FDA批准推出非处方用的持续性葡萄糖监测仪,股价大涨 [2][6] - Brown-Forman公司营收低于预期,主要是杰克丹尼尔威士忌销量下降 [3][9] 行业和公司总结 医疗器械行业 - Dexcom获得FDA批准推出首款非处方用的持续性葡萄糖监测仪,这是行业的一个重要突破 [2][6] 酒类行业 - Brown-Forman公司的主打产品杰克丹尼尔威士忌销量下降,拖累了公司整体营收 [3][9] 金融行业 - 摩根士丹利在中国裁员约9%,反映中国股市近期表现艰难 [11] 科技行业 - 希捷科技在投资者会议上表示当前季度业绩符合预期,可能不会大幅上调指引,令投资者失望 [10] 化工行业 - 阿尔伯玛尔公司为支付费用和偿还债务而发行新股,同时正在采取成本控制措施应对锂价下跌和电动车需求不确定性 [7] 保险行业 - 辛辛那提金融公司的承保业绩和个人险业务增长强劲 [8]

DexCom Inc. 新产品 Stelo - DexCom Inc. 最近宣布了其 Stelo 葡萄糖生物传感器的 FDA 认可，可供消费者无需处方购买[1] - Stelo 的非处方使用批准将进一步促进那些没有连续葡萄糖监测 (CGM) 保险覆盖的人群接触到尖端的 CGM 技术[2] - Stelo 是专为不使用胰岛素的 18 岁以上 Type 2 糖尿病患者设计的，是 Dexcom G7 的衍生产品，是一种小型可穿戴传感器，直接将葡萄糖信息传输到用户的智能手机[5] 市场趋势和预测 - DexCom 的股价过去六个月上涨了 17.3%，超过行业的 9.5% 增长和标普 500 指数的 14.2% 增长[3] - 根据 CDC 的数据，美国有大约 3800 万人被诊断患有糖尿病，其中约 90-95% 的人患有 Type 2 糖尿病，这种疾病最常见于 45 岁以上的人群，但现在也普遍发生在儿童和年轻成年人中[6] - 根据 MarketsandMarkets 的报告，全球数字糖尿病管理市场规模预计在 2023 年达到 189 亿美元，并预计到 2028 年以 13.6% 的增长率达到 358 亿美元[8] Dexcom 的业务发展 - Stelo 有望在 2024 年夏季开始在线无需处方购买[7] - FDA 对 Stelo 的批准可能会导致 CGM 领域产品的需求增加，从而带来更高的销售额，这对 Dexcom 的业务将提供重要推动[10] - Dexcom 在 2023 年 12 月宣布了 Dexcom G7 CGM 系统与 Tandem Diabetes Care 的 t: slim X2 胰岛素泵在美国的连接，这标志着 Dexcom G7 CGM 与 AID 的首次整合[11] - Dexcom 还揭开了位于爱尔兰加尔韦的新先进制造工厂，该工厂每年能生产数百万个 Dexcom rtCGM 传感器，有望为欧洲、中东和非洲地区的糖尿病患者做出更大贡献[12]

The most recent trading session ended with DexCom (DXCM) standing at $122.30, reflecting a +0.46% shift from the previouse trading day's closing. The stock outperformed the S&P 500, which registered a daily loss of 0.12%. Elsewhere, the Dow lost 0.25%, while the tech-heavy Nasdaq lost 0.41%.Shares of the medical device company have appreciated by 0.64% over the course of the past month, underperforming the Medical sector's gain of 3.58% and the S&P 500's gain of 4.83%.Investors will be eagerly watching for ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about DexCom (DXCM) .DexCom currently has an average brokerage recommen ...